Ocular Hypertension
📧 Sign up to get email alerts when something new happens for Ocular Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-04-17Clinical Trial Update: Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension [Phase 2]
Phase 2 trial comparing nebivolol and timolol suspensions to timolol solution for open-angle glaucoma and ocular hypertension; results poste…
-
FDA approval · 2024-04-05FDA Approved: TAFLUPROST — Original Application (Ingenus Pharmaceuticals, LLC)
The FDA approved Tafluprost as a generic product under an Original Application (ANDA) to Ingenus Pharmaceuticals, LLC.
-
FDA approval · 2024-03-29FDA Approved: TRAVOPROST OPHTHALMIC SOLUTION, 0.004% — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for travoprost ophthalmic solution 0.004% by Mylan Pharmaceuticals, expanding access to a generic pr…
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT [Phase 3]
A Phase III trial comparing DE-117 ophthalmic solution to latanoprost for safety and efficacy in open-angle glaucoma or ocular hypertension …
-
FDA approval · 2024-03-04FDA Approved: BRIMONIDINE — Original Application (Sandoz Inc)
The FDA approved Sandoz's original ANDA for brimonidine tartrate ophthalmic solution, establishing a generic version of this glaucoma medica…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2024-03-04Clinical Trial Update: A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension [Phase 4]
A Phase 4 study evaluating latanoprostene bunod for ocular hypertension was withdrawn.
-
FDA approval · 2024-02-20FDA Approved: DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALETAE — Supplemental Application (Indoco Remedies Limited)
FDA approved a supplemental application for a dorzolamide hydrochloride-timolol maleate eye drop manufactured by Indoco Remedies Limited.
-
FDA approval · 2024-02-20FDA Approved: DORZOLAMIDE AND TIMOLOL — Supplemental Application (Leading Pharma, LLC)
FDA approved a supplemental application for dorzolamide hydrochloride and timolol maleate ophthalmic solution from Leading Pharma, LLC.
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension [Phase 3]
Phase 3 trial comparing BREMEN Eye Drops to Combigan for ocular hypertension and primary open-angle glaucoma has completed.
-
FDA approval · 2024-02-20FDA Approved: DORZOLAMIDE HYDROCHLORIDE OPHTHALMIC — Supplemental Application (Florida Pharmaceutical Products, LLC)
FDA approved a supplemental application for dorzolamide hydrochloride ophthalmic solution filed by Florida Pharmaceutical Products, LLC.
-
FDA approval · 2024-02-13FDA Approved: BIMATOPROST — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application for bimatoprost from Apotex Corp., authorizing a regulatory change under the ANDA framework.
-
CLINICAL_TRIALS trial_result · 2024-02-07Clinical Trial Update: Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients. [Phase 1, Phase 2]
Clinical trial update reports safety assessment of T4090 eye drops in patients with ocular hypertension or glaucoma (Phase 1/Phase 2).
-
CLINICAL_TRIALS trial_result · 2024-01-18Clinical Trial Update: A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 clinical trial update for a therapeutic equivalence study in primary open-angle glaucoma or ocular hypertension; results posted.
-
FDA approval · 2023-12-27FDA Approved: LATANOPROST — Supplemental Application (Bausch & Lomb Incorporated)
The FDA approved a supplemental application for latanoprost filed by Bausch & Lomb Incorporated.
-
CLINICAL_TRIALS trial_result · 2023-12-20Clinical Trial Update: A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension [Phase 2]
Phase 2a randomized trial evaluating the efficacy and safety of TFC-003 in primary open-angle glaucoma or ocular hypertension.
-
CLINICAL_TRIALS trial_result · 2023-12-12Clinical Trial Update: Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. [Phase 4]
Phase 4 trial comparing two PF-formulation eye drops for open-angle glaucoma and ocular hypertension; the study has been terminated.
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension [Phase 2]
A Phase 2 clinical trial update for Travoprost ophthalmic topical cream addressing open-angle glaucoma and ocular hypertension is in progres…
-
CLINICAL_TRIALS trial_result · 2023-12-05Clinical Trial Update: A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension [Phase 3]
A Phase 3 confirmatory trial evaluating STN1012600 in adults with primary open-angle glaucoma or ocular hypertension has completed.
-
FDA approval · 2023-11-28FDA Approved: BIMATOPROST — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for bimatoprost filed by Alembic Pharmaceuticals Limited.
-
FDA approval · 2023-11-22FDA Approved: BRIMONIDINE TARTRATE — Original Application (Micro Labs Limited)
FDA approves the original application for brimonidine tartrate from Micro Labs Limited, adding a generic ophthalmic product for lowering int…
-
CLINICAL_TRIALS trial_result · 2023-11-21Clinical Trial Update: Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients [Phase 3]
Phase 3 trial comparing T4032 to Lumigan in ocular hypertension or glaucoma completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells [Phase 4]
Phase 4 trial evaluating the effect of benzalkonium chloride-preserved vs preservative-free latanoprost eye drops on conjunctival goblet cel…
-
CLINICAL_TRIALS trial_result · 2023-10-19Clinical Trial Update: A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension [Phase 1, Phase 2]
Clinical trial update for TO-O-1001 eye drops evaluating IOP-lowering effects in healthy subjects and patients with open-angle glaucoma or o…
-
FDA approval · 2023-10-10FDA Approved: LATANOPROST — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for latanoprost by Aurobindo Pharma Limited, approving a generic ophthalmic latanoprost product.…
-
CLINICAL_TRIALS trial_result · 2023-09-26Clinical Trial Update: Clinical Study Comparing Two Models of a Travoprost Intraocular Implant [Phase 3]
Phase 3 clinical study comparing two models of a travoprost intraocular implant in glaucoma and ocular hypertension completed with results p…